NYKODE
Nykode Therapeutics is a clinical-stage biopharmaceutical platform that develops technology for novel vaccines and immunotherapy against HPV-induced malignancies.
NYKODE
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2007-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.vaccibody.com
Total Employee:
11+
Status:
Active
Contact:
47 22 95 81 90
Total Funding:
31.73 M EUR
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Person Schema Gravatar Profiles WebEx
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Mette Vinge Head of Regulatory Affairs @ Nykode
Head of Regulatory Affairs
2021-02-01
Agnete B. Fredriksen Team Member @ Nykode
Team Member
Ole Henrik Brekke Chief Executive Officer @ Nykode
Chief Executive Officer
Mette Husbyn CTO @ Nykode
CTO
2017-10-01
Founder
Stock Details
Investors List
Norwegian Research Council
Norwegian Research Council investment in Venture Round - Nykode
Kreftforeningen
Kreftforeningen investment in Venture Round - Nykode
Kreftforeningen
Kreftforeningen investment in Venture Round - Nykode
Norwegian Research Council
Norwegian Research Council investment in Seed Round - Nykode
Norwegian Research Council
Norwegian Research Council investment in Grant - Nykode
Official Site Inspections
http://www.vaccibody.com
- Host name: hvaler.tornado-node.net
- IP address: 195.159.29.35
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "Nykode"
Company overview - nykode.com
Vaccibody AS, Gaustadalléen 21, 0349 Oslo, Norway www.vaccibody.com Org.nr. 990 646 066 1 Company overview Vaccibody AS is a privately held vaccine company based on the …See details»
Company Announcement - vaccibody.com
Nykode Therapeutics AS | Gaustadalléen 21, N-0349 Oslo, Norway | +47 22 95 81 93 3| nykode.com | Org. no. N-990 646 066 MVA Nykode Therapeutics ASSee details»
Annual Report 2020 - vaccibody.com
The organization from 24 employees at the end of 2019 to 51 at the end of 2020. We expect to continue to significantly increase the Vaccibody organization in order to execute our ambitious …See details»
Nykode - Crunchbase Company Profile & Funding
A therapeutic cancer vaccine candidate for treating HPV16-positive cancers, designed using Nykode’s Vaccibody™ technology platform. VB10.NEO: A cancer neoantigen vaccine in a …See details»
Vaccibody rebrands to Nykode and bags $925m deal …
Nov 24, 2021 The lucrative new partnership comes just over a year after Nykode (then Vaccibody) penned a deal with Roche-owned Genentech for the joint development and commercialisation of DNA-based neoantigen cancer …See details»
Vaccibody Becomes Nykode Therapeutics - Business Wire
Nov 23, 2021 Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company deSee details»
Vaccibody - VentureRadar
Vaccibody’s vaccines specifically target Antigen Presenting Cells. By intelligent design, Vaccibody’s vaccines can be tailored to induce the desired immune response profile …See details»
Vaccibody Company Profile | Management and Employees List
Vaccibody Profile and History. Founded in 2007 and headquartered in Oslo, Norway, Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of …See details»
Vaccibody rebrands as Nykode, and unveils big …
Nov 24, 2021 Vaccibody candidates have already shown robust CD8+ antigen-specific T cell responses in animal models and in patients with cancer, he added. Along with the Roche and Regeneron deals, Nykode is ...See details»
Vaccibody Company Information - Funding, Investors, and More
Track over 71,000 companies. Discover Fast-growing Global startups. Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.See details»
Annual report 2019 - vaccibody.com
In-human proof of concept for Vaccibody’s proprietary vaccine technology. In 2019, our organization grew from 19 to 24 employees. In October 2019, we were pleased to announce …See details»
Roche pays $200m for Vaccibody's cancer vaccine drug
Mar 24, 2025 Roche’s Genentech unit has paid $200 million to develop individualised cancer vaccines with Norwegian biotech Vaccibody, which focus on targets known as neoantigens …See details»
Company overview - nykode.com
Vaccibody AS, Gaustadalléen 21, 0349 Oslo, Norway www.vaccibody.com Org.nr. 990 646 066 4 Statement of financial position On March 31, 2018, Vaccibody had total assets of KNOK …See details»
Key figures 3rd quarter 9 months Full year - nykode.com
Vaccibody AS, Gaustadalléen 21, 0349 Oslo, Norway www.vaccibody.com Org.nr. 990 646 066 3 Financial review Profit and loss statement Revenue in the first nine months of 2017 of KNOK …See details»
October 2020 - Nykode
Vaccibody enters into worldwide license and collaboration with Genentech, a member of the Roche Group ... Build a world-class organization to deliver on the commitment Note: The …See details»
Vaccibody gets a new name and loads up with nearly $1B in …
Nov 23, 2021 Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for its neoantigen cancer vaccine, the Norwegian biotech has attracted yet another Big …See details»
Fully-funded Gavi, the Vaccine Alliance, is a lifeline for child ...
3 days ago Safeguarding children and adolescents from deadly, yet preventable diseases, such as polio, measles, diphtheria, pertussis, human papillomavirus and tetanus, among others, is …See details»
Vaccibody reports promising preclinical data with a second
Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses …See details»
Gavi, the Vaccine Alliance, has its billion dollar grant cut by ... - NPR
3 days ago Gavi, the Vaccine Alliance is a global health group that thinks in the billions.. Since its founding in 2000 the organization says it has played a role in vaccinating 1.1 billion children …See details»
COMPANY ANNOUNCEMENT - vaccibody.com
Vaccibody AS - Annual Report 2020 Oslo, Norway, April 21, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines …See details»